FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma
FDA Approves Pralsetinib for NSCLC with RET Gene Fusions
FDA Approves Trifluridine + Tipiracil with Bevacizumab for Previously Treated mCRC
FDA Approves Dostarlimab-gxly + Chemotherapy for Endometrial Cancer
FDA Approves Quizartinib for Newly Diagnosed AML
FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
FDA Approves Talazoparib + Enzalutamide for HRR Gene-mutated Metastatic Castration-resistant Prostate Cancer
FDA Grants Accelerated Approval to Glofitamab-gxbm
Updated NCCN Clinical Practice Guidelines Provides a New Recommendation for Ropeginterferon alfa-2b-njft
FDA Approves Olaparib + Abiraterone and Prednisone for BRCA-mutated Metastatic Prostate Cancer
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
FDA Approves Avapritinib for the Treatment of Adult Patients with Indolent Systemic Mastocytosis
FDA Approves Avapritinib for Indolent Systemic Mastocytosis
FDA Approves Epcoritamab-bysp for DLBCL
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Mobocertinib
FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-cell Lymphoma
FDA Approves Omidubicel for Patients with Hematologic Malignancies
FDA Approves Expanded Indication for Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
FDA Grants Accelerated Approval to Retifanlimab-dlwr for MCC
FDA Approves Dabrafenib + trametinib for Pediatric Patients with LGG
FDA Approves Pegfilgrastim-cbqv
FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
FDA Approves Dostarlimab-gxly for dMMR Endometrial Cancer
FDA Approves Sacituzumab Govitecan-hziy for HR-positive Breast Cancer
Biden Administration to End COVID-19 Public Health Emergency in May
FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer
FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC
FDA Approves Zanubrutinib for CLL or SLL
FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer
